Researchers found a significant benefit in adding carfilzomib to standard lenalidomide and dexamethasone treatment, extending disease-free periods by nearly 50%. The three-drug combination resulted in improved remission rates and overall survival, with patients reporting better quality of life.
A study by Dana-Farber Cancer Institute researchers found that levels of two microRNAs, let-7e and 106b/25, can predict progression-free survival in multiple myeloma patients. The study suggests that these microRNAs may also help doctors determine which patients are likely to have the best responses to different types of therapy.
In a groundbreaking clinical trial, nivolumab achieved complete or partial remission in 87% of patients with resistant Hodgkin lymphoma. The treatment targets the immune system, reactivating T cells to attack cancer cells.
A pilot study shows that 92% of children with relapsed leukemia respond to bioengineered T cells, with some patients remaining cancer-free for over two years. The personalized therapy offers the potential for long-term success in treating this highly aggressive form of acute lymphoblastic leukemia.
Researchers present new advances in treating relapsed and treatment-resistant lymphoma, including targeted therapies and stem cell transplantation, to improve patient outcomes. These studies show promising results for patients with HIV-associated lymphoma, where traditional treatments have been limited.
Studies presented at the ASH Annual Meeting show that immunotherapy drugs pembrolizumab and nivolumab are producing dramatic responses in Classical Hodgkin lymphoma patients. These results are promising for patients with few treatment options left, highlighting the potential of immunotherapies to work in various types of cancer.
New immunotherapy treatments aim to enable the body's natural defenses to recognize and destroy malignant cells. Studies present promising early data that encourage long-term outcomes among patients who have not responded to other therapies, including checkpoint inhibitors and drugs targeting the PD-1 pathway.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.